Ken Griffin’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18.7M Buy
63,500
+49,200
+344% +$13M ﹤0.01% 2719
2026
Q2
$3.24M Buy
14,300
+4,700
+49% +$837K ﹤0.01% 5549
2026
Q1
$1.66M Buy
9,600
+4,200
+78% +$779K ﹤0.01% 6507
2025
Q4
$1.08M Sell
5,400
-9,000
-63% -$1.63M ﹤0.01% 7225
2025
Q3
$2.25M Sell
14,400
-28,000
-66% -$4.45M ﹤0.01% 5838
2025
Q2
$6.43M Sell
42,400
-3,300
-7% -$440K ﹤0.01% 3693
2025
Q1
$6.88M Sell
45,700
-1,700
-4% -$285K ﹤0.01% 3390
2024
Q4
$8.75M Buy
47,400
+8,400
+22% +$1.62M ﹤0.01% 3151
2024
Q3
$7.68M Sell
39,000
-15,900
-29% -$3.3M ﹤0.01% 3297
2024
Q2
$11.3M Sell
54,900
-15,200
-22% -$3.44M ﹤0.01% 2621
2024
Q1
$19M Buy
70,100
+24,600
+54% +$5.87M ﹤0.01% 2118
2023
Q4
$10.8M Buy
45,500
+21,600
+90% +$4.25M ﹤0.01% 2742
2023
Q3
$4.68M Buy
23,900
+18,400
+335% +$3.78M ﹤0.01% 3756
2023
Q2
$1.16M Sell
5,500
-1,900
-26% -$378K ﹤0.01% 6160
2023
Q1
$1.49M Sell
7,400
-18,900
-72% -$4.28M ﹤0.01% 5920
2022
Q4
$5.73M Buy
26,300
+16,100
+158% +$3.52M ﹤0.01% 3630
2022
Q3
$2.01M Sell
10,200
-11,500
-53% -$2.48M ﹤0.01% 5577
2022
Q2
$4.64M Sell
21,700
-14,600
-40% -$3.57M ﹤0.01% 3941
2022
Q1
$10.3M Buy
36,300
+9,700
+36% +$2.99M ﹤0.01% 2899
2021
Q4
$10M Sell
26,600
-10,300
-28% -$4M ﹤0.01% 3068
2021
Q3
$15.2M Buy
36,900
+24,000
+186% +$10M ﹤0.01% 2411
2021
Q2
$4.77M Sell
12,900
-8,700
-40% -$2.91M ﹤0.01% 4543
2021
Q1
$6.26M Buy
21,600
+14,000
+184% +$3.89M ﹤0.01% 3797
2020
Q4
$1.9M Sell
7,600
-1,500
-16% -$357K ﹤0.01% 5447
2020
Q3
$2.06M Sell
9,100
-2,200
-19% -$457K ﹤0.01% 4654
2020
Q2
$1.97M Sell
11,300
-6,200
-35% -$989K ﹤0.01% 4612
2020
Q1
$2.21M Buy
17,500
+9,600
+122% +$1.44M ﹤0.01% 3977
2019
Q4
$1.21M Buy
7,900
+1,400
+22% +$194K ﹤0.01% 5261
2019
Q3
$860K Sell
6,500
-3,300
-34% -$442K ﹤0.01% 5848
2019
Q2
$1.39M Hold
9,800
– – ﹤0.01% 5143
2019
Q1
$1.42M Sell
9,800
-6,600
-40% -$867K ﹤0.01% 4992
2018
Q4
$1.86M Buy
16,400
+5,100
+45% +$639K ﹤0.01% 4260
2018
Q3
$1.52M Buy
11,300
+7,900
+232% +$975K ﹤0.01% 4855
2018
Q2
$382K Sell
3,400
-1,700
-33% -$184K ﹤0.01% 6810
2018
Q1
$544K Buy
5,100
+2,700
+113% +$291K ﹤0.01% 5746
2017
Q4
$263K Sell
2,400
-7,800
-76% -$849K ﹤0.01% 6669
2017
Q3
$1.1M Sell
10,200
-2,400
-19% -$247K ﹤0.01% 4179
2017
Q2
$1.27M Buy
12,600
+3,200
+34% +$295K ﹤0.01% 3752
2017
Q1
$846K Buy
+9,400
New +$798K ﹤0.01% 4245
2016
Q3
– Sell
-3,300
Closed -$272K – 7288
2016
Q2
$272K Buy
3,300
+400
+14% +$32.9K ﹤0.01% 5524
2016
Q1
$220K Sell
2,900
-5,100
-64% -$378K ﹤0.01% 5687
2015
Q4
$643K Sell
8,000
-6,200
-44% -$447K ﹤0.01% 4282
2015
Q3
$902K Buy
14,200
+13,100
+1,191% +$941K ﹤0.01% 4083
2015
Q2
$77K Hold
1,100
– – ﹤0.01% 7505
2015
Q1
$87K Hold
1,100
– – ﹤0.01% 7118
2014
Q4
$70K Sell
1,100
-400
-27% -$25.1K ﹤0.01% 7122
2014
Q3
$90K Sell
1,500
-53,300
-97% -$3.05M ﹤0.01% 6672
2014
Q2
$2.93M Buy
54,800
+45,600
+496% +$2.5M ﹤0.01% 2413
2014
Q1
$555K Buy
9,200
+7,900
+608% +$460K ﹤0.01% 4333
2013
Q4
$69K Sell
1,300
-900
-41% -$45.2K ﹤0.01% 5864
2013
Q3
$102K Sell
2,200
-500
-19% -$22.9K ﹤0.01% 5334
2013
Q2
$111K Hold
2,700
– – ﹤0.01% 5136

Other funds holding CRL

Ken Griffin's CRL Position: Q3 2026 in Review

Ken Griffin reduced its Charles River Laboratories (CRL) stake by 58% in Q3 2026, selling an estimated $182M and leaving 503,074 shares worth $148M. The position accounts for 0.02% of the portfolio, ranked #730.

Ken Griffin first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $271M in Q2 2026. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Ken Griffin held 503,074 shares of Charles River Laboratories worth $148M as of Q3 2026.
  • Ken Griffin sold 690,527 Charles River Laboratories shares in Q3 2026, an estimated $182M.
  • Charles River Laboratories made up 0.02% of Ken Griffin's portfolio in Q3 2026, its #730 holding.
  • Ken Griffin first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • Ken Griffin's Charles River Laboratories position peaked at $271M in Q2 2026.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.